# US 2023/0414563 A1 · Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin a for the treatment of neuropsychiatric and addictive disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414563 A1
- Document ID: US20230414563A1
- Status: Published application
- Kind: A1
- Application number: 18/308,260
- Filed: 2023-04-27
- Published: 2023-12-28
- Earliest claimed: 2015-11-17
- Inventors: Atlee Solomon
- Web page: https://patentgrep.com/patent/US20230414563A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0043: {Nose}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 36/3482: {Cannabis}
- A61K 36/537: Salvia (sage)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods of treating neuropsychiatric disorders including affective disorders and addiction involve intranasal or transdermal administration of a substantially selective kappa-opioid-receptor agonist that is also a partial D2 agonist, such as the compound salvinorin A. Also disclosed are intranasal, transdermal and/or inhalation systems for delivering the kappa-opioid-receptor agonist.

## Claims

### Claim 1

A method of treating tremor caused by administration of a substantially selective kappa-opioid-receptor agonist in a patient, the method comprising:
administering ketamine and/or a cannabinoid in a pharmaceutically acceptable preparation sufficient to treat the tremor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the substantially selective kappa-opioid-receptor agonist is salvinorin A.

### Claim 3 (depends on 2)

The method of claim 2, wherein the salvinorin A is administered intranasally.

### Claim 4 (depends on 2)

The method of claim 2, wherein the salvinorin A is administered transdermally.

### Claim 5 (depends on 1)

The method of claim 1, wherein the salvinorin A is administered by combustion and inhalation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient has an affective disorder.

### Claim 7 (depends on 6)

The method of claim 6, wherein the patient is treated with the substantially selective kappa-opioid-receptor agonist to treat the affective disorder.

### Claim 8 (depends on 7)

The method of claim 7, wherein the substantially selective kappa-opioid-receptor agonist is salvinorin A.

### Claim 9 (depends on 6)

The method of claim 6, wherein the affective disorder is depression, bipolar disorder, anxiety disorder, or depression.

### Claim 10 (depends on 1)

The method of claim 1, wherein the patient has an addiction.

### Claim 11 (depends on 10)

The method of claim 10, wherein the patient is treated with the substantially selective kappa-opioid-receptor agonist to treat the addiction.

### Claim 12 (depends on 11)

The method of claim 11, wherein the substantially selective kappa-opioid-receptor agonist is salvinorin A.

### Claim 13 (depends on 10)

The method of claim 10, wherein the addition is to an addictive behavior selected from the group consisting of eating, gambling, sex, pornography, video games, work, exercise, spiritual obsession, self-harm, travel and shopping addiction.

### Claim 14 (depends on 1)

The method of claim 1, wherein ketamine is administered without a cannabinoid.

### Claim 15 (depends on 1)

The method of claim 1, wherein a cannabinoid is administered without ketamine.

### Claim 16 (depends on 1)

The method of claim 1, wherein both ketamine and a cannabinoid is administered.

### Claim 17 (depends on 1)

The method of claim 1, wherein the cannabinoid is administered by combustion and inhalation.

### Claim 18 (depends on 1)

The method of claim 1, wherein the cannabinoid is administered by inhalation of a vaporized preparation.

### Claim 19 (depends on 1)

The method of claim 1, wherein the ketamine is administered intranasally.
